Lung Cancer

Top Story

FDA grants accelerated approval to brigatinib for ALK–positive NSCLC

April 28, 2017

The FDA granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase–positive non–small cell lung cancer who progressed on or are intolerant to crizotinib.

The FDA recommended a dose of 90 mg orally once daily for the first 7 days. After that, if tolerated, the dose can be increased to 180 mg orally once daily.

Five cancer prevention strategies

April 28, 2017
During his presidency, former U.S. President Barack Obama officially proclaimed April as National Cancer Control Month to “move forward in the fight against…
FDA News

FDA grants breakthrough therapy designation to lorlatinib for ALK–positive NSCLC

April 27, 2017
The FDA granted breakthrough therapy designation to lorlatinib for the treatment of patients with anaplastic lymphoma kinase–positive metastatic non–small…

Memorial Sloan Kettering Cancer Center names head of solid tumor oncology

April 26, 2017
Luis A. Diaz, MD, has been named head of the division of solid tumor oncology in the department of medicine at Memorial Sloan Kettering Cancer Center. Diaz —…
CME

Immuno-Oncology Forum: Focus on Non-Small Cell Lung Cancer

This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, Inc.; and Merck & Co., Inc.

Lung cancer accounts for 27% of all cancer deaths in the United States, making it the leading cause of cancer…
More »
Video
Meeting News Coverage

VIDEO: Studies address how to better use genetic testing

June 15, 2016
More »
Featured
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting

FDA News

FDA grants accelerated approval to brigatinib for ALK–positive NSCLC

April 28, 2017
The FDA granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase–positive…

Five cancer prevention strategies

April 28, 2017
During his presidency, former U.S. President Barack Obama officially proclaimed April as National Cancer Control Month to “move forward in the…

FDA News

FDA grants breakthrough therapy designation to lorlatinib for ALK–positive NSCLC

April 27, 2017
The FDA granted breakthrough therapy designation to lorlatinib for the treatment of patients with anaplastic lymphoma kinase–positive…

Memorial Sloan Kettering Cancer Center names head of solid tumor oncology

April 26, 2017
Luis A. Diaz, MD, has been named head of the division of solid tumor oncology in the department of medicine at Memorial Sloan Kettering Cancer…

Meeting NewsPerspective

Flu vaccine may cause immune-related adverse events with checkpoint inhibitors

April 26, 2017
Patients treated with PD-1/PD-L1 checkpoint inhibitors may be at an increased risk for adverse events after receiving the seasonal influenza…

In the Journals Plus

Intratumor heterogeneity increases risk for NSCLC recurrence, death

April 26, 2017
Intratumor heterogeneity mediated through chromosome instability increased risk for recurrence or death in patients with

FDA News

FDA issues warnings about fraudulent cancer treatments

April 25, 2017
The FDA issued warning letters to 14 U.S. companies that the agency contends are selling products fraudulently claimed to prevent, diagnose, treat or…

Abemaciclib regimen extends PFS among certain women with advanced breast cancer

April 24, 2017
The combination of abemaciclib plus an aromatase inhibitor significantly extended PFS among women with hormone receptor–positive…

Association of Community Cancer Centers names 2017-2018 president

April 22, 2017
Mark S. Soberman , MD, MBA, FACS, has been elected president of the Association of Community Cancer Centers for the 2017-2018 term…

PATH study will improve understanding of tobacco use, associations with health outcomes

April 20, 2017
More than one in four adults and nearly one in 10 young adults in the United States report some form of tobacco use. The majority say they use…

More Headlines »
Advertisement
Advertisement